Development and validation of the MMCD score to predict kidney replacement therapy in COVID-19 patients.
Acute kidney injury
COVID-19
Kidney replacement therapy
Risk factors
Risk prediction
Score
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
02 09 2022
02 09 2022
Historique:
received:
05
01
2022
accepted:
28
07
2022
entrez:
2
9
2022
pubmed:
3
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
Acute kidney injury (AKI) is frequently associated with COVID-19, and the need for kidney replacement therapy (KRT) is considered an indicator of disease severity. This study aimed to develop a prognostic score for predicting the need for KRT in hospitalised COVID-19 patients, and to assess the incidence of AKI and KRT requirement. This study is part of a multicentre cohort, the Brazilian COVID-19 Registry. A total of 5212 adult COVID-19 patients were included between March/2020 and September/2020. Variable selection was performed using generalised additive models (GAM), and least absolute shrinkage and selection operator (LASSO) regression was used for score derivation. Accuracy was assessed using the area under the receiver operating characteristic curve (AUC-ROC). The median age of the model-derivation cohort was 59 (IQR 47-70) years, 54.5% were men, 34.3% required ICU admission, 20.9% evolved with AKI, 9.3% required KRT, and 15.1% died during hospitalisation. The temporal validation cohort had similar age, sex, ICU admission, AKI, required KRT distribution and in-hospital mortality. The geographic validation cohort had similar age and sex; however, this cohort had higher rates of ICU admission, AKI, need for KRT and in-hospital mortality. Four predictors of the need for KRT were identified using GAM: need for mechanical ventilation, male sex, higher creatinine at hospital presentation and diabetes. The MMCD score had excellent discrimination in derivation (AUROC 0.929, 95% CI 0.918-0.939) and validation (temporal AUROC 0.927, 95% CI 0.911-0.941; geographic AUROC 0.819, 95% CI 0.792-0.845) cohorts and good overall performance (Brier score: 0.057, 0.056 and 0.122, respectively). The score is implemented in a freely available online risk calculator ( https://www.mmcdscore.com/ ). The use of the MMCD score to predict the need for KRT may assist healthcare workers in identifying hospitalised COVID-19 patients who may require more intensive monitoring, and can be useful for resource allocation.
Sections du résumé
BACKGROUND
Acute kidney injury (AKI) is frequently associated with COVID-19, and the need for kidney replacement therapy (KRT) is considered an indicator of disease severity. This study aimed to develop a prognostic score for predicting the need for KRT in hospitalised COVID-19 patients, and to assess the incidence of AKI and KRT requirement.
METHODS
This study is part of a multicentre cohort, the Brazilian COVID-19 Registry. A total of 5212 adult COVID-19 patients were included between March/2020 and September/2020. Variable selection was performed using generalised additive models (GAM), and least absolute shrinkage and selection operator (LASSO) regression was used for score derivation. Accuracy was assessed using the area under the receiver operating characteristic curve (AUC-ROC).
RESULTS
The median age of the model-derivation cohort was 59 (IQR 47-70) years, 54.5% were men, 34.3% required ICU admission, 20.9% evolved with AKI, 9.3% required KRT, and 15.1% died during hospitalisation. The temporal validation cohort had similar age, sex, ICU admission, AKI, required KRT distribution and in-hospital mortality. The geographic validation cohort had similar age and sex; however, this cohort had higher rates of ICU admission, AKI, need for KRT and in-hospital mortality. Four predictors of the need for KRT were identified using GAM: need for mechanical ventilation, male sex, higher creatinine at hospital presentation and diabetes. The MMCD score had excellent discrimination in derivation (AUROC 0.929, 95% CI 0.918-0.939) and validation (temporal AUROC 0.927, 95% CI 0.911-0.941; geographic AUROC 0.819, 95% CI 0.792-0.845) cohorts and good overall performance (Brier score: 0.057, 0.056 and 0.122, respectively). The score is implemented in a freely available online risk calculator ( https://www.mmcdscore.com/ ).
CONCLUSIONS
The use of the MMCD score to predict the need for KRT may assist healthcare workers in identifying hospitalised COVID-19 patients who may require more intensive monitoring, and can be useful for resource allocation.
Identifiants
pubmed: 36056335
doi: 10.1186/s12916-022-02503-0
pii: 10.1186/s12916-022-02503-0
pmc: PMC9438299
doi:
Substances chimiques
Dextrans
0
mitomycin C-dextran
0
Mitomycin
50SG953SK6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
324Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Nefrologia (Engl Ed). 2022 Jul-Aug;42(4):404-414
pubmed: 36460430
Ann Intern Med. 2019 Jan 1;170(1):51-58
pubmed: 30596875
Ann Intensive Care. 2021 Aug 6;11(1):123
pubmed: 34357478
BMC Med. 2015 Jan 06;13:1
pubmed: 25563062
Crit Care. 2013 Feb 04;17(1):204
pubmed: 23394211
Shock. 2017 Oct;48(4):411-417
pubmed: 28379920
J Am Soc Nephrol. 2021 Jan;32(1):151-160
pubmed: 32883700
Am J Emerg Med. 2021 May;43:149-157
pubmed: 33046323
Crit Care Med. 1985 Oct;13(10):818-29
pubmed: 3928249
Crit Care Med. 1998 Nov;26(11):1793-800
pubmed: 9824069
J Am Soc Nephrol. 2020 Sep;31(9):2145-2157
pubmed: 32669322
Int J Infect Dis. 2021 Jun;107:300-310
pubmed: 33444752
Kidney Int. 2020 Jul;98(1):209-218
pubmed: 32416116
Nephron. 2021;145(3):256-264
pubmed: 33780937
Blood Purif. 2021;50(4-5):499-505
pubmed: 33291098
Swiss Med Wkly. 2021 Mar 01;151:w20482
pubmed: 33706383
Am J Respir Crit Care Med. 2016 Aug 15;194(4):402-14
pubmed: 27337068
J Investig Med. 2020 Oct;68(7):1261-1270
pubmed: 32655013
J Am Geriatr Soc. 2021 May;69(5):1116-1127
pubmed: 33818759
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Ann Med. 2020 Nov;52(7):345-353
pubmed: 32643418
Blood Purif. 2021;50(4-5):520-530
pubmed: 33341806
Intensive Care Med. 2017 Jun;43(6):764-773
pubmed: 28130688
Ren Fail. 2021 Dec;43(1):1115-1123
pubmed: 34233570
Ann Intensive Care. 2019 Jul 1;9(1):74
pubmed: 31264042
Int J Nephrol. 2016;2016:6232909
pubmed: 27974972
J Am Med Inform Assoc. 2021 Jul 14;28(7):1480-1488
pubmed: 33706377
Clin J Am Soc Nephrol. 2021 Aug;16(8):1158-1168
pubmed: 34031183
J Clin Epidemiol. 2010 Aug;63(8):938-9; author reply 939
pubmed: 20189763
Lancet Respir Med. 2020 Jul;8(7):738-742
pubmed: 32416769
Mayo Clin Proc. 2018 Sep;93(9):1224-1235
pubmed: 30104041
Diabet Med. 2017 Jul;34(7):887-901
pubmed: 28164387
PLoS One. 2016 Jul 06;11(7):e0158765
pubmed: 27383068
Intensive Care Med. 2005 Oct;31(10):1345-55
pubmed: 16132892
Kidney Int. 2020 Jul;98(1):219-227
pubmed: 32327202
N Engl J Med. 2020 Jul 16;383(3):240-251
pubmed: 32668114
Nephrol Dial Transplant. 2011 Oct;26(10):3202-6
pubmed: 21765052
BMJ Open. 2020 Nov 10;10(11):e042573
pubmed: 33172950